Methods for diagnosis to allow prediction of the likelihood of preterm birth based upon the concentration of lipocalin-type prostaglandin D2 synthase (L-PGDS) in cervical vaginal secretions. In addition, specific prostaglandin D2 receptor antagonists may represent novel tocolytic therapeutics.

A method for determining the health status of an elderly individual by testing the sample extracted from the individual for the presence of biomarkers, the bio markers being autoantibodies to antigens comprising MAPK13, CD96, FKBP3, PPM1A, PHLDA1, GLRX3, FEN1 and AURKA, wherein the antigens may further comprise one or more of UBE2I, AAK1, YARS, ASPSCR1, CASP10, FHOD2, TCL1A and MAP4, wherein PHLDA1 and CD96 correspond to healthy, AURKA, FEN1, CASP10 and AAK1 correspond to intermediate health, and UBE2I, YARS, ASPSCR1, FHOD2, TCL1A, MAP4, MAPK13, FKBP3, PPM1A and GLRX3 correspond to unhealthy.

The invention relates to a method for identifying a cancer that is predicted to respond to treatment with a topoisomerase 1 (TOP1) inhibitor. The invention also extends to a method of treating cancer in a subject and a method of selecting a cancer patient for treatment with a cancer therapy. The invention further extends to use of cancer cells, such as primary colon cancer cells, as a biomarker for a patients response to treatment (insensitivity or sensitivity) with a particular chemotherapeutic agent, such as a TOP1 inhibitor.

Biomarkers and combinations thereof for determining risk and onset of preeclampsia, methods for their use and for diagnosis, prediction of risk, management, and treatment of preeclampsia in pregnant human females are provided.

The present invention relates to: a composition for differentially diagnosing Acanthamoeba keratitis, the composition comprising chorismate mutase antibodies; and an Acanthamoeba keratitis diagnosis kit using same. The composition comprising chorismate mutase antibodies according to the present invention causes an antigen-antibody reaction only specific to a chorismate mutase protein secreted from Acanthamoeba, thus making it possible to diagnose Acanthamoeba keratitis and differentiate the cause of Acanthamoeba keratitis more rapidly and accurately than existing methods for diagnosing Acanthamoeba keratitis. The composition is expected to be widely applicable to the production of Acanthamoeba keratitis diagnosis kits, therapeutic agents, contact lens disinfecting agents, and the like using the composition.

The present invention relates to novel compounds useful as sensors for the rapid and specific determination of the FKBP12 protein, a peptidyl-prolyl cis-trans isomerase (PPlase), the levels of which in the biological fluids of a subject change if the subject is affected by pathological conditions, in particular neurodegenerative diseases, such as the Parkinson's disease and the Alzheimer's syndrome, tumour pathologies, autoimmune diseases, or if that subject is in a phase of acute rejection after organ transplantation.

Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.

The invention relates to a method for finding inhibitors of the peptidyl-prolyl cis-trans isomerase FKBP1A or antibodies, proteins or molecules having a specific affinity to FKBP1A. The invention also relates to FKBP1A-specific siRNA, inhibitors of the expression of FKBP1A, inhibitors of the enzymatic activity of FKBP1A, and inhibitors of the interaction(s) of FKBP1A with interaction partner(s), in each case for the treatment of diseases, in particular cancers or neurodegenerative diseases. The invention further relates to the use of FKBP1A as a prognostic or diagnostic marker for cancers. The cancers are preferably mammary carcinoma, in particular triple-negative mammary carcinoma, in this case very particularly the mesenchymal stem-like sub-type.

Disclosed is a method of detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI). Also disclosed is a process for detecting a concentration of a biomarker in a human subject having or being at risk of developing Alzheimer's disease or Mild Cognitive Impairment (MCI) comprising (a) detecting a first concentration of lipocalin-PDS/TTR complex in a blood sample or urine sample from the subject, (b) determining a second concentration of PDS/TTR complex in a blood sample or urine sample from an unaffected individual, and (c) comparing the first and second concentrations, wherein a lower first concentration as compared to the second concentration is indicative of the subject having or being at risk of developing Alzheimer's disease.

Provided by the invention are methods for identifying therapeutic agents for treating multiple myeloma or another hematological malignancy, as well as methods for determining the prognosis of a patient with multiple myeloma or another hematological malignancy. The methods are based in part on the inventors' discovery that an extracellular form of cyclophilin A binds to CD147 expressed on multiple myeloma cells.